- About Us
- Research & Pipeline
- Investor Centre
- Media Centre
Kazia Therapeutics CEO Dr James Garner was a key speaker at a Finance News Network event in Sydney last week.
The Australian oncology-focused biotech Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia’s potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain.
The Australian phase 1 clinical trial of the drug Cantrixil for recurrent ovarian cancer could shape the next wave of clinical research into drugs targeting cancer stem cells, a peer-reviewed paper published in Expert Opinion on Orphan Drugs this month has found.
Kazia Therapeutics recently released preliminary data from its phase 1 clinical study of Cantrixil, a potential new treatment for recurrent ovarian cancer.
Sydney, 25 June 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to attend information briefing sessions to discuss the company’s recent activities.
A breakthrough new treatment for ovarian cancer that aims to stop the disease returning by killing off the cancer’s stem cells is undergoing safety trials in Australia.
Enter your email address to subscribe to our insights and receive notifications of new posts by email.
Required values are marked